Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409520 | 0.90 | MEN1 (0.80) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL4393425 | 0.87 | ALDH1A1 (0.76) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL3428650 | 0.86 | NPC1 (0.70) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL453594 | 0.85 | ALDH1A1 (0.76) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL4957798 | 0.84 | MEN1 (0.86) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL29175100 | 0.83 | ALDH1A1 (0.70) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL3424745 | 0.83 | PDE10A (0.62) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL1484185 | 0.83 | ALDH1A1 (0.66) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL411000 | 0.82 | PDE10A (1.00) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL29154649 | 0.81 | ALDH1A1 (0.76) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | claimed |
| US-8748440-B2 | Quinazolinone modulators of nuclear receptors | EXELIXIS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120064025-A1 | Quinazolinone Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| EP-1521746-B1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| EP-1521746-A1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X-Ceptor Therapeutics, Inc. (US) | 2005-04-13 | — | — | EP | disclosed |
| WO-2003076418-A1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064025-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | ALDH1A1 3161/4885MEN1 4424/4885KMT2A 3861/4885 |
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | ALDH1A1 3161/4885MEN1 4424/4885KMT2A 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.